Vanda Pharmaceuticals Inc. (VNDA) Q2 2024 Earnings Call Transcript

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET

Company Participants

Kevin Moran - Chief Financial Officer
Mihael Polymeropoulos - President, Chief Executive Officer & Chairman of the Board

Conference Call Participants

Charles Duncan - Cantor Fitzgerald
Andrew Tsai - Jefferies

Operator

Thank you for standing by. My name is Meg, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q2 2024 Vanda Pharmaceuticals, Inc. Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.

I would now like to turn the conference over to Mr. Kevin Moran, Vanda's Chief Financial Officer. You may begin.

Kevin Moran

Thank you, Meg. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceuticals second quarter 2024 performance. Our second quarter 2024 results were released this afternoon and are available on the SEC's EDGAR system and on our website www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website.

Joining me on today's call is Dr. Mihael Polymeropoulos, our President Chief Executive Officer and Chairman of the Board; and Tim Williams, our General Counsel. Following my introductory remarks, Mihael will update you on our ongoing activities. I will then comment on our financial results before we open the lines for your questions.

Before we proceed, I would like to remind everyone that various statements that we make on this call will be forward-looking statements within the meaning of federal securities laws. Our forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. These risks are described in the cautionary note regarding forward-looking statements, risk factors and Management's Discussion